A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Grant Data
Project Title
A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Principal Investigator
Dr Ho, James Chung Man
(Principal Investigator (PI))
Co-Investigator(s)
Dr Lam Jamie
(Co-Investigator)
Dr Wong Matthew
(Co-Investigator)
Dr Lam Chi Leung David
(Co-Investigator)
Duration
30
Start Date
2011-04-01
Amount
606761
Conference Title
A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Presentation Title
Keywords
non-small cell lung cancer
Discipline
Cancer
HKU Project Code
N/A
Grant Type
Pharmaceutical Industry - General Award
Funding Year
2010
Status
On-going